1022931-45-8Relevant articles and documents
Integration of lead optimization with crystallography for a membrane-bound ion channel target: Discovery of a new class of AMPA receptor positive allosteric modulators
Ward, Simon E.,Harries, Mark,Aldegheri, Laura,Austin, Nigel E.,Ballantine, Stuart,Ballini, Elisa,Bradley, Daniel M.,Bax, Benjamin D.,Clarke, Brian P.,Harris, Andrew J.,Harrison, Stephen A.,Melarange, Rosemary A.,Mookherjee, Claudette,Mosley, Julie,Dal Negro, Gianni,Oliosi, Beatrice,Smith, Kathrine J.,Thewlis, Kevin M.,Woollard, Patrick M.,Yusaf, Shahnaz P.
, p. 78 - 94 (2011/03/19)
A novel series of AMPAR positive modulators is described that were identified by high throughput screening. The molecules of the series have been optimized from a high quality starting point hit to afford excellent developability, tolerability, and effica
AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
-
Page/Page column 90, (2009/05/29)
The present invention relates to novel compounds of formula (I) or a salt thereof: wherein R1 is a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5, and n is 1 or 2; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.
COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE
-
, (2008/12/07)
Compound of formula (I) and salts thereof are provided: wherein A, R1, R, R2 are as defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.